Dear Editor,

MYD88 p.L265P has recently been identified as a considerably recurrent mutation in lymphoplasmacytic lymphomas with an IgM monoclonal protein (Waldenström's macroglobulinemia [WM]). The mutation was also described as a common event in several other lymphoproliferative disorders, including diffuse large B-cell lymphoma and primary central nervous system (CNS) lymphoma [1].

Detecting MYD88 p.L265P mutations was subsequently proposed as critical to the differential diagnosis of WM, multiple myeloma, and marginal zone lymphoma [2, 3]. A more recent study indicated that MYD88 mutation frequency in WM was slightly lower than was previously assumed. Patients with wild-type MYD88, however, often show amplifications on chromosome 3 at the 3p22 locus, which includes the MYD88 gene [4]. Because MYD88 plays a role in activating nuclear factor (NF)-κB signaling, its mutation will likely be relevant to targeted therapeutics [5].

Previously published methods for the detection of MYD88 p.L265P include high-resolution melting analysis (HRMA), allele specific polymerase chain reaction (AL-PCR), and direct DNA sequencing [2, 6].

The purpose of this study was to establish a pyrosequencing assay using decalcified formalin-fixed and paraffin-embedded (dFFPE) bone marrow trephine biopsies from 14 patients with WM and 10 patients with multiple myeloma. To extend the application of the technique, we used the assay to evaluate fresh bone marrow mononuclear cell samples (n=5) and peripheral blood samples (n=5) collected from five of the 14 WM patients (Cases 1, 4-7). All samples were collected as part of standard clinical care and diagnosed at the Reference Center for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein, Campus Luebeck, Germany. All studies were approved by the Ethics Committee at the University of Luebeck and were in accordance with the Declaration of Helsinki.

Pyrosequencing was performed as described previously [7]. DNA was extracted with the QiaAmp Mini Kit 250 (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. A short sequence of DNA encompassing the mutation site was amplified by using a specific pair of primers, one of which was biotinylated (in this case the reverse primer). Next, a single strand of the amplified mutation region was prepared by using streptavidin-coated Sepharose beads to specifically bind the biotin tag on the reverse primer. Sequencing was subsequently performed on a PyroMark Q24 platform (Qiagen) following incubation with a forward sequencing primer. Allele frequency was quantified utilizing the PyroMark Software (Qiagen). Primers

© The Korean Society for Laboratory Medicine.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: August 12, 2013
Revision received: September 25, 2013
Accepted: December 17, 2013

Corresponding author: Niklas Gebauer
Department of Pathology, University Hospital of Schleswig-Holstein, Campus Luebeck, Ratzenburger Allee 160, Luebeck 23538, Germany
Tel: +49-451-5003728, Fax: +49-451-5003328
E-mail: Niklas.Gebauer@uksh.de

© The Korean Society for Laboratory Medicine.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
were designed and synthesized (Tib Molbiol, Berlin, Germany) as follows: MYD88-265-forward: 5'-GAATGTGTGCCAGGGGTACTT; MYD88-265-reverse: 5'-Bioteg-TCAGGATGCTGGGGAACTA; MYD88-265-sequencing-forward: 5'-CCCATCAGAAGCGAC.

In agreement with the literature, 11 of 14 (78.6%) WM samples contained the MYD88 p.L265P mutation [2]. Wild-type sequence was found in 3 samples (21.4%). Poulain et al. [4] recently suggested that an alternative genomic aberration affecting the MYD88 gene, e.g., 3p22 amplification, might be relevant in such cases promoting a functionally equivalent activating effect on NF-κB signaling. All cases of multiple myeloma tested negative. Morphological and molecular aspects of two selected cases are displayed in Fig. 1. MYD88 p.L265P mutations with an allele frequency of 5% or higher were reproducibly detected with the pyrosequencing assay. For comparison, all samples were sequenced by the Sanger method, which generated a sensitivity cut-off at an allele burden of approximately 20%. Results from the analysis of fresh bone marrow and peripheral blood samples showed that the sensitivity was comparable to that seen in the dFFPE samples, detecting MYD88 mutations in all five cases (allele burden 8-48%). Clinical, hematological and molecular features of the study group are briefly summarized in Table 1.

Compared to previously published methods, pyrosequencing provides a fast, reliable, highly sensitive, and economic method to detect MYD88 p.L265P [2, 6]. Because it quantifies the allele burden, pyrosequencing is useful for follow-up diagnostics and monitoring disease activity. Its robustness and applicability to dFFPE samples render it useful for routine hematopathological diagnostics.

---

Fig. 1. Bone marrow trephine biopsy and smear from a case of Waldenström’s macroglobulinemia harboring the MYD88 p.L265P mutation with an allele frequency of 46% as determined by pyrosequencing assay (A), and a patient suffering from multiple myeloma without the MYD88 p.L265P mutation (B) (hematoxylin-eosin, ×200, Pappenheim stain, ×400). Corresponding quantification of allele burden using the PyroMark software in the above cases of Waldenström’s macroglobulinemia (C) and multiple myeloma (D).
Table 1. Clinical, hematological and molecular features of the study group

| Case No. | Sex | Age (yr) | Diagnosis | Hb (g/dL) | WBC (×10^9/L) | PLT (×10^9/L) | MYD88 p.L265P allele burden in dFFPE samples, BM and PB-Pyro* | MYD88 p.L265P-Sanger† |
|----------|-----|----------|-----------|-----------|---------------|---------------|-----------------------------------------------------------|----------------------|
| 1        | M   | 60       | WM        | 11.9      | 3.6           | 234           | Positive 6% (BM: 8%, PB: 8%)§                              | No                   |
| 2        | F   | 61       | WM        | 10.7      | 4.6           | 134           | Negative                                                 | No                   |
| 3        | F   | 74       | WM        | 12.3      | 6.9           | 221           | Negative                                                 | No                   |
| 4        | M   | 69       | WM        | 9.2       | 7.2           | 254           | Positive 42% (BM: 44%, PB: 37%)§                           | Yes                  |
| 5        | F   | 54       | WM        | 11.3      | 4.5           | 178           | Positive 48% (BM: 48%, PB: 39%)§                           | Yes                  |
| 6        | M   | 72       | WM        | 10.4      | 5.3           | 146           | Positive 36% (BM: 39%, PB: 28%)§                           | Yes                  |
| 7        | M   | 49       | WM        | 12.8      | 3.8           | 157           | Positive 27% (BM: 28%, PB: 24%)§                           | Yes                  |
| 8        | F   | 71       | WM        | 10.6      | 7.4           | 187           | Negative                                                 | No                   |
| 9        | M   | 53       | WM        | 11.9      | 5.6           | 261           | Positive 61%                                              | Yes                   |
| 10       | F   | 73       | WM        | 8.1       | 3.8           | 197           | Positive 52%                                              | Yes                   |
| 11       | F   | 54       | WM        | 8.2       | 6.1           | 520           | Positive 23%                                              | Yes†                 |
| 12       | M   | 58       | WM        | 9.4       | 7.9           | 384           | Positive 24%                                              | Yes†                 |
| 13       | M   | 74       | WM        | 8.7       | 6.7           | 267           | Positive 5%                                               | No                   |
| 14       | F   | 75       | WM        | 10.2      | 5.8           | 310           | Positive 24%                                              | Yes                  |
| 15       | M   | 49       | MM        | 11.6      | 3.8           | 178           | Negative                                                 | No                   |
| 16       | F   | 49       | MM        | 13.1      | 5.3           | 242           | Negative                                                 | No                   |
| 17       | M   | 68       | MM        | 12.3      | 5.2           | 244           | Negative                                                 | No                   |
| 18       | M   | 35       | MM        | 11.3      | 6.4           | 216           | Negative                                                 | No                   |
| 19       | F   | 71       | MM        | 10.8      | 7.4           | 188           | Negative                                                 | No                   |
| 20       | M   | 73       | MM        | 12.2      | 8.1           | 321           | Negative                                                 | No                   |
| 21       | F   | 78       | MM        | 8.8       | 6.9           | 178           | Negative                                                 | No                   |
| 22       | M   | 62       | MM        | 11.4      | 5.4           | 228           | Negative                                                 | No                   |
| 23       | F   | 70       | MM        | 10.9      | 4.7           | 199           | Negative                                                 | No                   |
| 24       | F   | 66       | MM        | 9.8       | 4.8           | 167           | Negative                                                 | No                   |

*As detected by pyrosequencing; †Detection of MYD88 p.L265P by means of Sanger sequencing; ‡Reliable detectability by means of Sanger sequencing yet in close proximity to the sensitivity cut-off; §Results from pyrosequencing on dFFPE samples confirmed by comparative investigation of fresh bone marrow mononuclear cells (BM) and peripheral blood samples (PB).

Abbreviations: M, male; F, female; WBC, white blood cell; PLT, platelets; dFFPE, decalcified formalin-fixed and paraffin-embedded; WB, Waldenström’s macroglobulinemia; MM, multiple myeloma.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

Acknowledgments

We thank Tanja Oeltermann and Annette Aufseß for their skilled and dedicated technical assistance.

REFERENCES

1. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470:115-9.
2. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012;367:826-33.
3. Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammapathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013;121:2051-8.
4. Poulain S, Roumier C, Decambron A, Renneville A, Herbaux C, Bertrand E, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 2013;121:4504-11.
5. Loiarro M, Ruggiero V, Sette C. Targeting the Toll-like receptor/interleukin 1 receptor pathway in human diseases: rational design of MYD88 inhibitors. Clin Lymphoma Myeloma Leuk 2013;13:222-6.
6. Wang CZ, Lin J, Qian J, Shao R, Xue D, Qian W, et al. Development of high-resolution melting analysis for the detection of the MYD88 L265P
mutation. Clin Biochem 2013;46:385-7.
7. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, et al. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol 2006;169:471-81.